drugset / Trial / NCT00625703

Pharmacokinetics of Linezolid in Children With Cystic Fibrosis

NCT00625703

NaSingle-groupOpen-labelOther

Summary

To determine the pharmacokinetic profile of IV (intravenous) and PO (oral) formulations of linezolid among children with cystic fibrosis and establish a dose regimen that will be safe and effective.

Timeline

Start
2010-12
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Linezolid Other / unclassified 15 mg/kg Intravenous

Indications